115 related articles for article (PubMed ID: 31944316)
1. Identification of the targeted therapeutic potential of doxycycline for a subset of gastric cancer patients.
Pandian J; Panneerpandian P; Devanandan HJ; Sekar BT; Balakrishnan K; Selvarasu K; Muthupandi K; Ganesan K
Ann N Y Acad Sci; 2020 May; 1467(1):94-111. PubMed ID: 31944316
[TBL] [Abstract][Full Text] [Related]
2. Delineation of gastric tumors with activated ERK/MAPK signaling cascades for the development of targeted therapeutics.
Pandian J; Ganesan K
Exp Cell Res; 2022 Jan; 410(1):112956. PubMed ID: 34864005
[TBL] [Abstract][Full Text] [Related]
3. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing.
Li M; Chen L; Qu Y; Sui F; Yang Q; Ji M; Shi B; Chen M; Hou P
Oncotarget; 2017 May; 8(22):36319-36330. PubMed ID: 28422736
[TBL] [Abstract][Full Text] [Related]
4. Tanshinone IIA inhibits gastric carcinoma AGS cells by decreasing the protein expression of VEGFR and blocking Ras/Raf/MEK/ERK pathway.
Su CC
Int J Mol Med; 2018 Apr; 41(4):2389-2396. PubMed ID: 29393362
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer.
Liang B; Wang S; Zhu XG; Yu YX; Cui ZR; Yu YZ
World J Gastroenterol; 2005 Feb; 11(5):623-8. PubMed ID: 15655810
[TBL] [Abstract][Full Text] [Related]
6. Abacavir induces the transcriptional activity of YY1 and other oncogenic transcription factors in gastric cancer cells.
Panneerpandian P; Devanandan HJ; Marimuthu A; Karthikeyan C; Ganesan K
Antiviral Res; 2020 Feb; 174():104695. PubMed ID: 31846633
[TBL] [Abstract][Full Text] [Related]
7. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
8. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
9. Pro-apoptotic role of the MEK/ERK pathway in ursodeoxycholic acid-induced apoptosis in SNU601 gastric cancer cells.
Lim SC; Duong HQ; Parajuli KR; Han SI
Oncol Rep; 2012 Oct; 28(4):1429-34. PubMed ID: 22824956
[TBL] [Abstract][Full Text] [Related]
10. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
11. MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy.
Zhang X; Ma L; Qi J; Shan H; Yu W; Gu Y
Mol Cell Biochem; 2015 Dec; 410(1-2):101-10. PubMed ID: 26318312
[TBL] [Abstract][Full Text] [Related]
12. Induction of glucose-regulated protein 78 by chronic hypoxia in human gastric tumor cells through a protein kinase C-epsilon/ERK/AP-1 signaling cascade.
Song MS; Park YK; Lee JH; Park K
Cancer Res; 2001 Nov; 61(22):8322-30. PubMed ID: 11719466
[TBL] [Abstract][Full Text] [Related]
13. Tanshinone IIA inhibits gastric carcinoma AGS cells through increasing p-p38, p-JNK and p53 but reducing p-ERK, CDC2 and cyclin B1 expression.
Su CC
Anticancer Res; 2014 Dec; 34(12):7097-110. PubMed ID: 25503137
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
15. H pylori stimulates proliferation of gastric cancer cells through activating mitogen-activated protein kinase cascade.
Chen YC; Wang Y; Li JY; Xu WR; Zhang YL
World J Gastroenterol; 2006 Oct; 12(37):5972-7. PubMed ID: 17009395
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
17. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
18. Development of a cell-based pathway modulator screening system to screen the targeted cancer therapeutic candidates.
Panneerpandian P; Ganesan K
Hum Cell; 2021 Mar; 34(2):445-456. PubMed ID: 33405176
[TBL] [Abstract][Full Text] [Related]
19. Identification of kinases and kinase inhibitors for the differential targeting of Wnt/β-catenin signaling in gastric cancer subtypes.
Bhaskar Rao D; Devanandan HJ; Ganesan K
Drug Dev Res; 2021 Dec; 82(8):1182-1192. PubMed ID: 34002415
[TBL] [Abstract][Full Text] [Related]
20. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
